Should You Buy the Dip in Eli Lilly Stock Right Now?
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly dropped by as much as 8% and ended the day down around 6%. Year-to-date, share prices are down about 1.4%.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Eli Lilly's operational performance is strong ... shares have seen downside of 14.8% at a time when the S&P 500 is up 2.6%. The picture isn't as bad when we compare the data to my original ...
Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...
are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P 500 index's SPX worst performer.
The S&P 500 edged higher while the Nasdaq dipped after a volatile session on Tuesday as investors gauged inflation data and ...
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...
The U.S. stock market experienced mixed results on Tuesday. The Dow Jones index climbed over 220 points to 42,518.28, while ...
Key Takeaways The S&P 500 jumped 1% on Friday, Jan. 17, 2025, heading into a three-day weekend on a high note as prospects ...
Shares of Eli Lilly were already in an intermediate-term decline before the announcement. The stock has dropped 25% from its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback